Kalaris Therapeutics KLRS
NASDAQ KLRS
$2.02 -0.05 (-2.42%)
At close: Oct 21, 2026 · 4:00 PM EDT

Kalaris Therapeutics (KLRS) Debt Ratio (2024)

Updated

Kalaris Therapeutics' Debt Ratio came in at 3.17 for Q4 2024.

Analysis

Kalaris Therapeutics (KLRS) Debt Ratio (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 0.39
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 0.24
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 0.52
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 0.42
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 0.08
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 0.28
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 0.60
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 0.53
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 0.31
10 Kalaris Therapeutics 47.48 Mn -46.02 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 3.17
API Access

Kalaris Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=KLRS&period=max&api_key=YOUR_API_KEY